

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/236276 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/072099

(22) International Filing Date:

04 May 2022 (04.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/201,537 04 May 2021 (04.05.2021) US

(71) Applicant: **AGENUS INC.** [US/US]; 3 Forbes Road, Lexington, Massachusetts 02421 (US).

(72) Inventors: **CHAND, Dhan Sidhartha**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **JAWAD, Zahra**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **IGNATOVICH, Olga**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **RAMSAY, Nicola Anne**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **CAMPBELL, Spencer**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **WENSLEY, Beth**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **BRIEND, Emmanuel Cyrille Pascal**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **BUSHELL, K. Mark**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **MORIN, Benjamin Maxime**; 3 Forbes Road, Lexington, Massachusetts 02421 (US). **ILKOW, Veronica Franciszka**; 3 Forbes Road, Lexington, Massachusetts 02421 (US).

(74) Agent: **WILKINS, Andrew T.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

19 January 2023 (19.01.2023)

(54) Title: ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES, AND METHODS OF USE THEREOF

(57) Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.



WO 2022/236276 A3